Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer: a 'useless intraoperative fever' or the next hot voice in the surgical management of the 'silent killer'?
| Autor: | C. Iavazzo, J. Spiliotis |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Standard of care business.industry Obstetrics and Gynecology General Medicine medicine.disease 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine Hyperthermic intraperitoneal chemotherapy 030212 general & internal medicine Ovarian cancer business DISEASE RELAPSE |
| Zdroj: | Archives of Gynecology and Obstetrics. 298:673-674 |
| ISSN: | 1432-0711 0932-0067 |
| Popis: | The aim of our opinion letter is to highlight the recent findings in the field of hyperthermic intraperitoneal chemotherapy (HIPEC) use in ovarian cancer management. Two recent studies reveal that ovarian cancer patients treated with HIPEC can extend their survival independently of the timing offered—either at the initial cytoreductive effort or at the time of disease relapse. The research field is flourishing and further data are awaited from randomised control trials. Although, HIPEC is not considered yet as the standard of care in the management of ovarian cancer patients, the initial findings of its use are promising. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink